{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:47:32Z","timestamp":1792478852497,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"DOI":"10.2146\/ajhp150290","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T11:16:19Z","timestamp":1455880579000},"page":"279-285","source":"Crossref","is-referenced-by-count":26,"title":["I.V. minocycline revisited for infections caused by multidrug-resistant organisms"],"prefix":"10.1093","volume":"73","author":[{"given":"Benjamin","family":"Colton","sequence":"first","affiliation":[{"name":"National Institutes of Health Clinical Center, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"McConeghy","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Schreckenberger","sequence":"additional","affiliation":[{"name":"Stritch School of Medicine, Loyola University Chicago, Maywood, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry H.","family":"Danziger","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago, College of Pharmacy, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041102402979000_b1-0730279","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. www.cdc.gov\/drugresistance\/threat-report-2013 (accessed 2015 Feb 12)."},{"key":"key\n\t\t\t\t2019041102402979000_b2-0730279","unstructured":"Siegel JD Rhinehart E Jackson M Chiarello L . Management of multi-drug-resistant organisms in health-care settings. www.cdc.gov\/hicpac\/pdf\/MDRO\/MDROGuideline2006.pdf (accessed 2015 Feb 16)."},{"key":"key\n\t\t\t\t2019041102402979000_b3-0730279","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum \u03b2-lactamase\u2013 producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019041102402979000_b4-0730279","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijid.2014.10.014","article-title":"An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics","volume":"30C","author":"Kassamali","year":"2015","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t2019041102402979000_b5-0730279","first-page":"335","article-title":"Clinical evaluation of minocycline","volume":"8","author":"Frisk","year":"1968","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b6-0730279","first-page":"865","article-title":"Minocycline administered intravenously: pharmacologic and clinical experience","volume":"16","author":"Clark","year":"1974","journal-title":"Curr Ther Res Clin Exp"},{"key":"key\n\t\t\t\t2019041102402979000_b7-0730279","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijantimicag.2009.06.021","article-title":"Minocycline\u2014an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii","volume":"34","author":"Bishburg","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019041102402979000_b8-0730279","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1093\/cid\/ciu531","article-title":"Minocycline: an old drug for a new bug: multidrug-resistant Acinetobacter baumannii","volume":"59","author":"Goff","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041102402979000_b9-0730279","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol Mol Biol Rev"},{"issue":"suppl 6","key":"key\n\t\t\t\t2019041102402979000_b10-0730279","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/cid\/ciu706","article-title":"Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options","volume":"59","author":"Castanheira","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041102402979000_b11-0730279","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/AAC.8.6.713","article-title":"Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs","volume":"8","author":"Barza","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b12-0730279","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/nar\/25.6.1219","article-title":"Interaction of tetracycline with RNA: photoincorporation into ribosomal RNA of Escherichia coli","volume":"25","author":"Oehler","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"key\n\t\t\t\t2019041102402979000_b13-0730279","doi-asserted-by":"crossref","first-page":"16576","DOI":"10.1074\/jbc.274.23.16576","article-title":"Effects of tetracycline and spectinomycin on the tertiary structure of ribosomal RNA in the Escherichia coli 30 S ribosomal subunit","volume":"274","author":"Noah","year":"1999","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019041102402979000_b14-0730279","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/jac\/30.6.737","article-title":"Efflux-based antibiotic resistance mechanisms: the evidence for increasing prevalence","volume":"6","author":"Chopra","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b15-0730279","volume-title":"Minocin (minocycline for injection) package insert","year":"2014"},{"key":"key\n\t\t\t\t2019041102402979000_b16-0730279","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.47.1.400-404.2003","article-title":"Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates","volume":"47","author":"Milatovic","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b17-0730279","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/cid\/cis492","article-title":"In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates","volume":"55","author":"Saravolatz","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041102402979000_b18-0730279","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1128\/AAC.01099-06","article-title":"In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii","volume":"51","author":"Scheetz","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b19-0730279","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/civ048","article-title":"Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance","volume":"60","author":"Qureshi","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041102402979000_b20-0730279","article-title":"Performance standards for antimicrobial susceptibility testing, 25th informational supplement","volume-title":"CLSI document M100-S25","year":"2015"},{"key":"key\n\t\t\t\t2019041102402979000_b21-0730279","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.resmic.2004.10.008","article-title":"Distribution of tetracycline resistance genes in genotypically related and unrelated multiresistant Acinetobacter baumannii strains from different European hospitals","volume":"156","author":"Huys","year":"2005","journal-title":"Res Microbiol"},{"key":"key\n\t\t\t\t2019041102402979000_b22-0730279","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.06365-11","article-title":"Evaluation of clinical outcomes in patients with bloodstream infections due to gram-negative bacteria according to carbapenem MIC stratification","volume":"56","author":"Esterly","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b23-0730279","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/JCM.00001-14","article-title":"Major variation in MICs of tigecycline in gram-negative bacilli as a function of testing method","volume":"52","author":"Marchaim","year":"2014","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t2019041102402979000_b24-0730279","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/dkm142","article-title":"High tigecycline resistance in multidrug-resistant Acinetobacter baumannii","volume":"60","author":"Thamlikitkul","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b25-0730279","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/jac\/dki386","article-title":"Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines","volume":"56","author":"Hope","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b26-0730279","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/cpt1973145852","article-title":"Pharmacokinetic studies on minocycline in man","volume":"1","author":"Macdonald","year":"1973","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019041102402979000_b27-0730279","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1440-1681.1974.tb00552.x","article-title":"Minocycline excretion and distribution in relation to renal function in man","volume":"1","author":"Carney","year":"1974","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"key\n\t\t\t\t2019041102402979000_b28-0730279","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.8.5.532","article-title":"Pharmacokinetics of minocycline in renal failure","volume":"8","author":"Welling","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b29-0730279","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF01969570","article-title":"One-dose and multiple-dose kinetics of minocycline in patients with renal disease","volume":"7","author":"Sklenar","year":"1977","journal-title":"Agents Actions"},{"key":"key\n\t\t\t\t2019041102402979000_b30-0730279","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/cpt1978242233","article-title":"Minocycline and doxycycline kinetics in chronic renal failure","volume":"24","author":"Heaney","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019041102402979000_b31-0730279","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b32-0730279","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1201\/b13787-78","article-title":"Minocycline","volume-title":"Kucers\u2019 the use of antibiotics","author":"Horrevorts","year":"2010","edition":"6th ed."},{"key":"key\n\t\t\t\t2019041102402979000_b33-0730279","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF01642233","article-title":"Studies on the absorption and excretion of minocycline and a comparison with doxycycline","volume":"2","author":"Alestig","year":"1974","journal-title":"Infection"},{"key":"key\n\t\t\t\t2019041102402979000_b34-0730279","first-page":"1","article-title":"Pharmacodynamics of antimicrobials: general concepts and applications","volume-title":"Antimicrobial pharmacodynamics in theory and clinical practice","author":"Craig","year":"2002"},{"key":"key\n\t\t\t\t2019041102402979000_b35-0730279","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1128\/AAC.00922-07","article-title":"Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model","volume":"52","author":"Bowker","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b36-0730279","first-page":"194","article-title":"Clinical evaluation of intravenous minocycline","volume":"15","author":"Rogers","year":"1977","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"key\n\t\t\t\t2019041102402979000_b37-0730279","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/13.suppl_C.17","article-title":"Treatment of severe staphylococcal infections with a rifampicin-minocycline association","volume":"13","author":"Clumeck","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b38-0730279","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/IPC.0b013e31828bbb82","article-title":"Use of intravenous minocycline for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) and resistant gram-negative organisms: experience in a tertiary care hospital","volume":"22","author":"Bishburg","year":"2014","journal-title":"Infect Dis Clin Pract"},{"key":"key\n\t\t\t\t2019041102402979000_b39-0730279","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1007\/s00134-003-1811-2","article-title":"Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"29","author":"Wood","year":"2003","journal-title":"Intensive Care Med"},{"key":"key\n\t\t\t\t2019041102402979000_b40-0730279","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/IPC.0b013e318245d50a","article-title":"A stewardship approach to combating multidrug-resistant Acinetobacter baumanii infections with minocycline","volume":"20","author":"Jankowski","year":"2012","journal-title":"Infect Dis Clin Pract"},{"key":"key\n\t\t\t\t2019041102402979000_b41-0730279","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1093\/cid\/ciu594","article-title":"Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center","volume":"59","author":"Pogue","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041102402979000_b42-0730279","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0885066610377975","article-title":"Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"25","author":"Chan","year":"2010","journal-title":"J Intensive Care Med"},{"issue":"suppl 6","key":"key\n\t\t\t\t2019041102402979000_b43-0730279","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1093\/cid\/ciu593","article-title":"Bad bugs need old drugs: a stewardship program\u2019s evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections","volume":"59","author":"Goff","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041102402979000_b44-0730279","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1128\/AAC.01097-08","article-title":"In vitro activities of tigecycline, minocycline, and colistin\u2013tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group","volume":"53","author":"Arroyo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041102402979000_b45-0730279","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/009127007101100504","article-title":"Clinical pharmacologic studies with minocycline","volume":"11","author":"Bernard","year":"1971","journal-title":"J Clin Pharmacol New Drugs"},{"key":"key\n\t\t\t\t2019041102402979000_b46-0730279","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/STROKEAHA.110.582601","article-title":"Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study","volume":"41","author":"Fagan","year":"2010","journal-title":"Stroke"},{"key":"key\n\t\t\t\t2019041102402979000_b47-0730279","unstructured":"Business Wire. FDA approves new formulation of minocin\u00ae (minocycline) for injection. www.businesswire.com\/news\/home\/20150420005501\/en\/FDA-Approves-Formulation-MINOCIN%C2%AE-minocycline-Injection (accessed 2016 Jan 4)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/5\/279\/28334866\/ajhp0279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T23:09:05Z","timestamp":1692227345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/5\/279\/5101651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp150290","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,3,1]]},"published":{"date-parts":[[2016,3,1]]}}}